Therapy News and Research

RSS

New molecular diagnostic test precisely identifies insect venom allergy

Bees, wasps and bumble bees pose a real health threat to individuals with venom allergy. One sting from these insects may cause potentially life-threatening anaphylactic reactions in people with these conditions.

14 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

Calcium-sensing receptor plays key role in lethal lung cancer complication

A protein previously thought not to exist in adult human lungs not only is present in normal and cancerous lung tissue, scientists have found, but it also has a major role in the development of a lethal complication of some lung cancers.

14 Jun 2011

Cinryze data on hereditary angioedema presented at EAACI 2011

ViroPharma Incorporated today announced that data relating to Cinryze from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.

14 Jun 2011

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

Fox Chase Cancer Center, one of the nation's leading cancer research and treatment institutions, today announced it has entered into an agreement with Life Technologies Corporation that will underpin a new program to provide next-generation sequencing analysis of solid tumors.

14 Jun 2011

Sleep-targeted intervention can help prevent suicidal thoughts

Treating sleep problems with cognitive-behavioral therapy for insomnia can reduce suicidal ideation, suggests a research abstract that will be presented Tuesday, June 14, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Severe sleep apnea increases risk of gestational diabetes and preterm birth in pregnant women

Sleep apnea is associated with an increased risk of adverse pregnancy outcomes, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC (APSS).

13 Jun 2011

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Alexion Pharmaceuticals, Inc. today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes.

13 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

Accuray acquires TomoTherapy

Accuray Incorporated announced today that it has completed its previously announced acquisition of TomoTherapy Incorporated.

13 Jun 2011

Trimeris, Synageva enter definitive merger agreement

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, and Trimeris, Inc., announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.

13 Jun 2011

Patients with multiple sclerosis can benefit from group therapy sessions

Offering Multiple Sclerosis sufferers emotional support through group therapy sessions could improve their quality of life and save the NHS almost £500 per patient, a study at The University of Nottingham has discovered.

13 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

Left ventricular assist device increases incidence of internal bleeding in heart failure patients

The incidence of internal bleeding was higher in the most commonly implanted heart device than in an earlier model, according to two studies at Henry Ford Hospital in Detroit.

13 Jun 2011

Risky behavior, psychiatric disorders and substance abuse contribute to opioid overdose

Deaths related to prescription opioid therapy are under intense scrutiny, prompting those in pain medicine-clinicians, patient advocates, and regulators-to understand the causes behind avoidable mortality in legitimately treated patients.

13 Jun 2011

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.

13 Jun 2011

UNAIDS, PEPFAR announce campaign to eliminate MTCT of HIV by 2015

A team led by UNAIDS and PEPFAR on Thursday at the U.N. High Level Meeting on AIDS announced a plan to virtually eliminate mother-to-child transmission of HIV by 2015 by "ensuring that all women, especially pregnant ones, have access to quality life-saving HIV prevention and treatment services - for themselves and their children," BBC News reports.

13 Jun 2011

S. African government program reduced MTCT HIV transmission rate to 3.5%, study shows

The South African government's program to prevent mother-to-child transmission (PMTCT) of HIV has reduced the rate of virus transmission to about 3.5 percent, "potentially sparing some 67,000 babies from HIV infection," according to research presented on Wednesday by the Medical Research Council at the 5th South African AIDS Conference in Durban, Health-e/allAfrica.com reports.

13 Jun 2011

Therapy News and Research

New molecular diagnostic test precisely identifies insect venom allergy

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

Calcium-sensing receptor plays key role in lethal lung cancer complication

Cinryze data on hereditary angioedema presented at EAACI 2011

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

Sleep-targeted intervention can help prevent suicidal thoughts

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Severe sleep apnea increases risk of gestational diabetes and preterm birth in pregnant women

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Accuray acquires TomoTherapy

Trimeris, Synageva enter definitive merger agreement

Patients with multiple sclerosis can benefit from group therapy sessions

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

Left ventricular assist device increases incidence of internal bleeding in heart failure patients

Risky behavior, psychiatric disorders and substance abuse contribute to opioid overdose

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

UNAIDS, PEPFAR announce campaign to eliminate MTCT of HIV by 2015

S. African government program reduced MTCT HIV transmission rate to 3.5%, study shows

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News